Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1997 Mar;90(3):323–329. doi: 10.1111/j.1365-2567.1997.00323.x

Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice.

D P Snider 1, B J Underdown 1, M R McDermott 1
PMCID: PMC1456616  PMID: 9155636

Abstract

Covalent conjugates of hen egg lysozyme (HEL) and anti-major histocompatibility complex (MHC) class II monoclonal antibodies (mAb) were used to immunize mice intranasally. Three weeks after intranasal (IN) priming, mice responded rapidly to IN challenge with a mixture of HEL and cholera toxin (CT), by producing large titres of anti-HEL IgA and IgG1 antibody in serum, and IgA antibody in nasal secretions. No secondary response to HEL plus CT occurred in mice that received no priming or mice primed with HEL alone. The secondary serum IgG antibody response was dominated by the IgG1 subclass. HEL combined with CT adjuvant worked much better than HEL alone in producing the secondary response. Control conjugates, containing an IgG isotype-matched mAb without specificity for mouse tissues, provided poor priming. Mice expressing MHC class II molecules, to which the anti-MHC II mAb could not bind, produced a weak antibody response compared with those that expressed the appropriate. MHC class II molecule. Our results demonstrate that immunotargeting to MHC class II molecules via the IN route allows priming of the local IgA and circulating IgG antibody, and indicate that this technique is a feasible approach for delivery of subunit vaccines in the upper respiratory tract.

Full text

PDF
323

Images in this article

325Figure 1
on p.325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aramaki Y., Fujii Y., Yachi K., Kikuchi H., Tsuchiya S. Activation of systemic and mucosal immune response following nasal administration of liposomes. Vaccine. 1994 Oct;12(13):1241–1245. doi: 10.1016/0264-410x(94)90251-8. [DOI] [PubMed] [Google Scholar]
  2. Cahill E. S., O'Hagan D. T., Illum L., Barnard A., Mills K. H., Redhead K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine. 1995 Apr;13(5):455–462. doi: 10.1016/0264-410x(94)00008-b. [DOI] [PubMed] [Google Scholar]
  3. Carayanniotis G., Barber B. H. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature. 1987 May 7;327(6117):59–61. doi: 10.1038/327059a0. [DOI] [PubMed] [Google Scholar]
  4. Elson C. O., Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol. 1984 Jun;132(6):2736–2741. [PubMed] [Google Scholar]
  5. Estrada A., McDermott M. R., Underdown B. J., Snider D. P. Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine. 1995 Jul;13(10):901–907. doi: 10.1016/0264-410x(95)00012-p. [DOI] [PubMed] [Google Scholar]
  6. Fazekas G., Rosenwirth B., Dukor P., Gergely J., Rajnavölgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol. 1994 Dec;24(12):3063–3067. doi: 10.1002/eji.1830241222. [DOI] [PubMed] [Google Scholar]
  7. Fine P. E., Rodrigues L. C. Modern vaccines. Mycobacterial diseases. Lancet. 1990 Apr 28;335(8696):1016–1020. doi: 10.1016/0140-6736(90)91074-k. [DOI] [PubMed] [Google Scholar]
  8. Graham M. B., Dalton D. K., Giltinan D., Braciale V. L., Stewart T. A., Braciale T. J. Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J Exp Med. 1993 Nov 1;178(5):1725–1732. doi: 10.1084/jem.178.5.1725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hameleers D. M., van der Ven I., Biewenga J., Sminia T. Mucosal and systemic antibody formation in the rat after intranasal administration of three different antigens. Immunol Cell Biol. 1991 Apr;69(Pt 2):119–125. doi: 10.1038/icb.1991.18. [DOI] [PubMed] [Google Scholar]
  10. Heukeshoven J., Dernick R. Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis. 1988 Jan;9(1):28–32. doi: 10.1002/elps.1150090106. [DOI] [PubMed] [Google Scholar]
  11. Hiroi T., Fujihashi K., McGhee J. R., Kiyono H. Characterization of cytokine-producing cells in mucosal effector sites: CD3+ T cells of Th1 and Th2 type in salivary gland-associated tissues. Eur J Immunol. 1994 Nov;24(11):2653–2658. doi: 10.1002/eji.1830241113. [DOI] [PubMed] [Google Scholar]
  12. Iwasaki T., Nozima T. Defense mechanisms against primary influenza virus infection in mice. I. The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production. J Immunol. 1977 Jan;118(1):256–263. [PubMed] [Google Scholar]
  13. Langermann S., Palaszynski S., Sadziene A., Stover C. K., Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature. 1994 Dec 8;372(6506):552–555. doi: 10.1038/372552a0. [DOI] [PubMed] [Google Scholar]
  14. Lövgren K., Kåberg H., Morein B. An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol. 1990 Dec;82(3):435–439. doi: 10.1111/j.1365-2249.1990.tb05467.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McDermott M. R., Befus A. D., Bienenstock J. The structural basis for immunity in the respiratory tract. Int Rev Exp Pathol. 1982;23:47–112. [PubMed] [Google Scholar]
  16. Mjaaland S., Fossum S. Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur J Immunol. 1990 Jul;20(7):1457–1461. doi: 10.1002/eji.1830200708. [DOI] [PubMed] [Google Scholar]
  17. Nedrud J. G., Liang X. P., Hague N., Lamm M. E. Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol. 1987 Nov 15;139(10):3484–3492. [PubMed] [Google Scholar]
  18. Reuman P. D., Keely S. P., Schiff G. M. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV. J Med Virol. 1991 Nov;35(3):192–197. doi: 10.1002/jmv.1890350309. [DOI] [PubMed] [Google Scholar]
  19. Snapper C. M., Mond J. J. Towards a comprehensive view of immunoglobulin class switching. Immunol Today. 1993 Jan;14(1):15–17. doi: 10.1016/0167-5699(93)90318-F. [DOI] [PubMed] [Google Scholar]
  20. Snider D. P., Kaubisch A., Segal D. M. Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med. 1990 Jun 1;171(6):1957–1963. doi: 10.1084/jem.171.6.1957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Snider D. P., Marshall J. S., Perdue M. H., Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol. 1994 Jul 15;153(2):647–657. [PubMed] [Google Scholar]
  22. Spit B. J., Hendriksen E. G., Bruijntjes J. P., Kuper C. F. Nasal lymphoid tissue in the rat. Cell Tissue Res. 1989 Jan;255(1):193–198. doi: 10.1007/BF00229081. [DOI] [PubMed] [Google Scholar]
  23. Tamura S., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol. 1992 Aug 1;149(3):981–988. [PubMed] [Google Scholar]
  24. Tamura S., Kurata H., Funato H., Nagamine T., Aizawa C., Kurata T. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit. Vaccine. 1989 Aug;7(4):314–320. doi: 10.1016/0264-410x(89)90192-8. [DOI] [PubMed] [Google Scholar]
  25. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 1994 Apr;12(5):419–426. doi: 10.1016/0264-410x(94)90118-x. [DOI] [PubMed] [Google Scholar]
  26. Treanor J. J., Mattison H. R., Dumyati G., Yinnon A., Erb S., O'Brien D., Dolin R., Betts R. F. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med. 1992 Oct 15;117(8):625–633. doi: 10.7326/0003-4819-117-8-625. [DOI] [PubMed] [Google Scholar]
  27. Weltzin R., Lucia-Jandris P., Michetti P., Fields B. N., Kraehenbuhl J. P., Neutra M. R. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J Cell Biol. 1989 May;108(5):1673–1685. doi: 10.1083/jcb.108.5.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wu H. Y., Russell M. W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun. 1993 Jan;61(1):314–322. doi: 10.1128/iai.61.1.314-322.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Xu-Amano J., Aicher W. K., Taguchi T., Kiyono H., McGhee J. R. Selective induction of Th2 cells in murine Peyer's patches by oral immunization. Int Immunol. 1992 Apr;4(4):433–445. doi: 10.1093/intimm/4.4.433. [DOI] [PubMed] [Google Scholar]
  30. de Haan A., Geerligs H. J., Huchshorn J. P., van Scharrenburg G. J., Palache A. M., Wilschut J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine. 1995 Feb;13(2):155–162. doi: 10.1016/0264-410x(95)93129-w. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES